Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Pregnancy TSH Variations Prompt Erroneous Thyroid Disease Diagnosis

By LabMedica International staff writers
Posted on 22 Jun 2020
Thyroid-stimulating hormone is a pituitary hormone that stimulates the thyroid gland to produce thyroxine, and then triiodothyronine which stimulates the metabolism of almost every tissue in the body.

Physiologic variations in thyroid-stimulating hormone (TSH) concentrations may lead to a misclassification of subclinical thyroid disease for some healthy pregnant women, possibly subjecting women to unnecessary treatment. More...


Endocrinologists at the Medical University of Lodz (Rzgowska, Poland) and their colleagues assessed baseline concentrations of free T4, free T3, as well as TSH at 30 minute intervals (between 7.00 and 9.00 hours) in 110 healthy pregnant women, age 30.2 ± 6.0 years, 9.9 ± 2.4 weeks of gestation and in 19 female controls age 28.9 ± 10.7. The scientists analyzed data from the healthy pregnant women (mean age, 30 years; mean BMI, 24.9 kg/m²; mean gestational age, 9.9 weeks), hospitalized at Polish Mother’s Memorial Hospital Research Institute between 2017 and 2019, as well as the non-pregnant healthy women (mean age, 29 years; mean BMI, 28.3 kg/m²).

Based on data from 550 measurements, the team found that mean TSH concentrations were 1.62 mIU/L and 1.67 mIU/L among pregnant women and controls, respectively. Women who were Thyroid peroxidase (TPO) antibody-positive had a higher TSH concentration versus women who were TPO antibody-negative (mean TSH, 3.17 mIU/L versus 1.62 mIU/L). Taking into account the highest TSH out of five consecutive measurements, the scientists found that 20.9% of pregnant women had a TSH measurement greater than 2.5 mIU/L and 9.1% of pregnant women had a TSH measurement greater than 4 mIU/L.

When considering the lowest TSH value, the investigators observed TSH measurements greater than 2.5 mIU/L in 12.7% of pregnant women and TSH measurements greater than 4 mIU/L in 3.6% of pregnant women. The team found that the discrepancy was even greater for women who were TPO antibody-negative, varying between 21.2% versus 8.1% for a TSH greater than 2.5 mIU/L when considering the highest versus. the lowest TSH values, and varying between 6.06% versus 1.01% for a TSH greater than 4 mIU/L when considering the highest versus the lowest TSH values. They also found that TSH concentrations varied by 39.5% for pregnant women and by 42.47% among controls, with no between-group difference.

Andrzej Lewinski, MD, PhD, a Professor of Endocrinology and the senior author of the study, said, “Any decisions to instigate treatment, particularly during such a sensitive period like pregnancy, should be based on clear data that define what TSH and thyroid hormone concentrations are abnormal, as well as evidence of definite benefit of treatment. Furthermore, assessment of thyroid function should be performed during the first trimester of pregnancy, as fetal development is then almost entirely dependent on maternal thyroid hormone concentrations. In such circumstances, it is mandatory to ascertain that one is dealing with a genuine abnormality and not with physiological variations in hormone concentrations.” The study was published on May 19, 2020 in the journal Clinical Endocrinology.

Related Links:
Medical University of Lodz


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.